LEADER 01372nam  2200397   450 
001 9910707230503321
005 20160624085406.0
035   $a(CKB)5470000002463205
035   $a(OCoLC)952175585
035   $a(OCoLC)995470000002463205
035   $a(EXLCZ)995470000002463205
100   $a20160624d2004      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aMedicare reimbursement for existing end stage renal disease drugs
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2004.
215   $a1 online resource (v, 16 pages) $cillustrations
300   $aTitle from title screen (viewed June 23, 2016).
300   $a"May 2004."
300   $a"OEI-03-04-00120."
517 1 $aMedicare reimbursement for ESRD drugs
606   $aMedicare$xClaims administration
606   $aChronic renal failure$xTreatment$zUnited States$xFinance
606   $aDrugs$zUnited States$xCosts
615  0$aMedicare$xClaims administration.
615  0$aChronic renal failure$xTreatment$xFinance.
615  0$aDrugs$xCosts.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707230503321
996   $aMedicare reimbursement for existing end stage renal disease drugs$93310623
997   $aUNINA